Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Teeru Bihani"'
Autor:
Sunil Pancholi, Nikiana Simigdala, Ricardo Ribas, Eugene Schuster, Mariana Ferreira Leal, Joanna Nikitorowicz-Buniak, Camilla Rega, Teeru Bihani, Hitisha Patel, Stephen R. Johnston, Mitch Dowsett, Lesley-Ann Martin
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-15 (2022)
Abstract The selective oestrogen receptor (ER) degrader (SERD), fulvestrant, is limited in its use for the treatment of breast cancer (BC) by its poor oral bioavailability. Comparison of the orally bioavailable investigational SERD elacestrant, versu
Externí odkaz:
https://doaj.org/article/acca486d20374dd3829e01221da2e13f
Autor:
Hitisha K. Patel, Nianjun Tao, Kyung-Min Lee, Mariela Huerta, Heike Arlt, Tara Mullarkey, Steven Troy, Carlos L. Arteaga, Teeru Bihani
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-17 (2019)
Abstract Background Addition of CDK4/6 inhibitors (CDK4/6i) to endocrine therapy significantly increased progression-free survival, leading to their approval and incorporation into the metastatic breast cancer treatment paradigm. With these inhibitor
Externí odkaz:
https://doaj.org/article/781ea0c332464bf09c872f6a6b3d11ae
Autor:
Sabina C. Cosulich, Stephen Green, Oona Delpuech, Robert McEwen, Urszula M. Polanska, Christine M. Chresta, Martin Pass, Kurt G. Pike, Teresa Klinowska, Graham Bigley, Barry R. Davies, Zoe Howard, Michael Grondine, James W.T. Yates, Celina M. D'Cruz, Teeru Bihani, Jon Curwen, Sylvie M. Guichard
Pharmacokinetics modelling of AZD2014 intermittent dosing schedule.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0aab7bc29f3860fec33ee0af943823b0
https://doi.org/10.1158/1535-7163.22505970.v1
https://doi.org/10.1158/1535-7163.22505970.v1
Autor:
Sabina C. Cosulich, Stephen Green, Oona Delpuech, Robert McEwen, Urszula M. Polanska, Christine M. Chresta, Martin Pass, Kurt G. Pike, Teresa Klinowska, Graham Bigley, Barry R. Davies, Zoe Howard, Michael Grondine, James W.T. Yates, Celina M. D'Cruz, Teeru Bihani, Jon Curwen, Sylvie M. Guichard
HCC1428-eveR and HCC1428-LTED-eveR cell lines resistant to everolimus remain sensitive to dual mTORC1/2 inhibitor AZD2014.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cbbecc1501da9a57ed9b2de4b62242f
https://doi.org/10.1158/1535-7163.22505973
https://doi.org/10.1158/1535-7163.22505973
Autor:
Sabina C. Cosulich, Stephen Green, Oona Delpuech, Robert McEwen, Urszula M. Polanska, Christine M. Chresta, Martin Pass, Kurt G. Pike, Teresa Klinowska, Graham Bigley, Barry R. Davies, Zoe Howard, Michael Grondine, James W.T. Yates, Celina M. D'Cruz, Teeru Bihani, Jon Curwen, Sylvie M. Guichard
Supplementary data on cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20b4e1c79aa3f231a187d9a02f72da17
https://doi.org/10.1158/1535-7163.22505964
https://doi.org/10.1158/1535-7163.22505964
Autor:
Sabina C. Cosulich, Stephen Green, Oona Delpuech, Robert McEwen, Urszula M. Polanska, Christine M. Chresta, Martin Pass, Kurt G. Pike, Teresa Klinowska, Graham Bigley, Barry R. Davies, Zoe Howard, Michael Grondine, James W.T. Yates, Celina M. D'Cruz, Teeru Bihani, Jon Curwen, Sylvie M. Guichard
Pharmacokinetics and PK/PD relationships for AZD2014
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98473f6fc21ae8f367d8c0594f8ae037
https://doi.org/10.1158/1535-7163.22505979
https://doi.org/10.1158/1535-7163.22505979
Autor:
Sabina C. Cosulich, Stephen Green, Oona Delpuech, Robert McEwen, Urszula M. Polanska, Christine M. Chresta, Martin Pass, Kurt G. Pike, Teresa Klinowska, Graham Bigley, Barry R. Davies, Zoe Howard, Michael Grondine, James W.T. Yates, Celina M. D'Cruz, Teeru Bihani, Jon Curwen, Sylvie M. Guichard
Supplementary table 1: Biochemical and cellular activity of AZD2014. Supplementary table 2: Biochemical activity of AZD2014. Supplementary table 3: Anti proliferative activity of AZD2014 in a panel of ER+, endocrine resistant and LTED cell lines. Sup
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::364da65de5509dc97972c00cb9c5f42b
https://doi.org/10.1158/1535-7163.22505976.v1
https://doi.org/10.1158/1535-7163.22505976.v1
Autor:
Fiona Garner, Gary Hattersley, Dinesh M. Purandare, Jeffrey L. Brown, Hai Jiang, Nianjun Tao, Heike Arlt, Hitisha K. Patel, Teeru Bihani
Supplementary Table
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fccab120142b849f2163b795a443272
https://doi.org/10.1158/1078-0432.22462364
https://doi.org/10.1158/1078-0432.22462364
Autor:
Fiona Garner, Gary Hattersley, Dinesh M. Purandare, Jeffrey L. Brown, Hai Jiang, Nianjun Tao, Heike Arlt, Hitisha K. Patel, Teeru Bihani
Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e0affc5e557f62615a9ed3d3a8ee7f2
https://doi.org/10.1158/1078-0432.22462370
https://doi.org/10.1158/1078-0432.22462370
Autor:
Fiona Garner, Gary Hattersley, Dinesh M. Purandare, Jeffrey L. Brown, Hai Jiang, Nianjun Tao, Heike Arlt, Hitisha K. Patel, Teeru Bihani
Purpose: Estrogen receptor–positive (ER+) breast cancers are typically treated with endocrine agents, and dependence on the ER pathway is often retained even after multiple rounds of antiestrogen therapy. Selective estrogen receptor degraders (SERD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ff3c157a1016b23c8bad8c1454b7e71
https://doi.org/10.1158/1078-0432.c.6525089
https://doi.org/10.1158/1078-0432.c.6525089